Showing 311-320 of 1560 results for "".
Biogeneric Drugs
https://reachmd.com/programs/washington-health-report/biogeneric-drugs/1801/Biogenerics are generic versions of biotech drugs made from cells and other living organisms. They could save consumers and the health care system a lot of money. Here to tell us about them is a reporter who has been covering health care for National Journal for more than a decade. She written extenDermatology and CTCL: Recommendations
https://practicaldermatology.com/series/dermwire-tv/dermatology-and-ctcl-recommendations/26798/Larisa J. Geskin, MD, Professor of Dermatology at Columbia University Medical Center, discusses "Time to Act: A Global Patient-Focused Consensus for Improving Care in Cutaneous T-Cell Lymphoma (CTCL)," a global consensus statement from Kyowa Kirin that recommends, among other things, that dermatologThe Future of MS Management: Novel Agents and Clinical Approaches
https://reachmd.com/programs/neurofrontiers/program-name/36360/The multiple sclerosis (MS) treatment landscape is rapidly evolving, with novel approaches on the horizon that may transform care for progressive patients. Explore the latest phase 3 data on BTK inhibitors like tolebrutinib and gain insights into ongoing CAR T-cell and remyelination research, includOverall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
https://reachmd.com/programs/project-oncology/overall-survival-with-neoadjuvant-therapy-in-hnscc/32999/Despite recent therapeutic advances, long-term survival in head and neck squamous cell carcinoma (HNSCC) remains suboptimal. A new study compared overall survival outcomes associated with neoadjuvant systemic therapy in patients with resectable disease. Hear from Dr. Vanessa Helou as she shares theThe Challenges of Diagnosing Diabetes in Children
https://reachmd.com/programs/diabetes-discourse/the-challenges-of-diagnosing-diabetes-in-children/4688/The incidence of diabetes is increasing per year in the US and globally. The trend data suggests that obesity may be driving autoimmune beta cell failure. Some have questioned whether excess obesity or adiposity might be playing a role in this increased incidence of type 1 diabetes or whether healthGenetic Tumor Testing
https://reachmd.com/programs/focus-on-cancer/genetic-tumor-testing/4365/A new program at Massachusetts General Hospital in Boston includes extracting the DNA from its cancer patients’ tumors to determine which abnormalities occur in the tumor cells, specific to the type of tumor. From these results, physicians hope to create better, targeted cancer therapies. Host Dr. LImmune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
https://reachmd.com/programs/project-oncology/immune-checkpoint-inhibitors-show-promise-in-patients-with-oncogene-driver-negative-nsclc-who-have-never-smoked/33000/A multi-institutional study presented at ASCO 2025 offers critical new insights into a long-overlooked subset of non-small cell lung cancer (NSCLC) patients: never-smokers without actionable oncogenic drivers. Read about the study’s findings on the key predictors of response to immune checkpoint inhModernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
https://reachmd.com/programs/project-oncology/modernizing-pulmonary-assessment-reassessing-race-neutral-interpretation-in-practice/39036/As medicine shifts toward race-neutral lung function interpretation, new challenges emerge in ensuring equitable access to care. Dr. Ajay Sheshadri explores how race-neutral spirometry may impact patient selection for lung resection surgery and hematopoietic cell transplantation. Dr. SheshadrA New Model of Healthcare Delivery
https://reachmd.com/programs/conversations-on-health-care/a-new-model-of-healthcare-delivery/6928/This week, Mark and Margaret speak with Dr. Joseph C. Kvedar, MD, Founder and Director of the Center for Connected Health. Dr. Kvedar is creating innovative programs to leverage information technology - cell phones, computers, networked devices and simple remote health monitoring tools - to help proDo We Need to Temper our Enthusiasm for Incretin-Based Therapy?
https://reachmd.com/programs/diabetes-discourse/do-we-need-to-temper-our-enthusiasm-for-incretin-based-therapy/5947/There have been impressive results with incretin-based therapy for patients with type 2 diabetes: improved A1C, beta-cell preservation and weight loss are some of the benefits. But do healthcare professionals need to temper their enthusiasm for this novel therapy? Join host Dr. Steven Edelman and hi